{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:13:14Z","timestamp":1790266394432,"version":"4.1.0"},"reference-count":91,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["770854"],"award-info":[{"award-number":["770854"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["101094980"],"award-info":[{"award-number":["101094980"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","award":["2569\/24"],"award-info":[{"award-number":["2569\/24"]}],"id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","award":["2133\/23"],"award-info":[{"award-number":["2133\/23"]}],"id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["75N93020D00005"],"award-info":[{"award-number":["75N93020D00005"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["SCR_026557"],"award-info":[{"award-number":["SCR_026557"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003975","name":"Israel Cancer Association","doi-asserted-by":"publisher","award":["150031"],"award-info":[{"award-number":["150031"]}],"id":[{"id":"10.13039\/501100003975","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005190","name":"Melanoma Research Alliance","doi-asserted-by":"publisher","award":["917324"],"award-info":[{"award-number":["917324"]}],"id":[{"id":"10.13039\/100005190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.xcrm.2025.102506","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T15:36:26Z","timestamp":1765899386000},"page":"102506","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Lymphodepleting chemotherapy potentiates neoantigen-directed T cell therapy by enhancing antigen presentation"],"prefix":"10.1016","volume":"6","author":[{"given":"Shira","family":"Sagie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomer","family":"Babu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Tabachnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ido","family":"Livneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nele P.","family":"Quast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nofar","family":"Gumpert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Shomuradova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew I.","family":"Raybould","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronen","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry","family":"Malko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Alfia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talal","family":"Ben Lulu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Alon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Kutuzov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirie","family":"Zerbib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polina","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talya","family":"Wasserman-Bartov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Benedek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yishai","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chani","family":"Stossel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Kamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talia","family":"Golan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roni","family":"Oren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merav","family":"Shmueli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osnat","family":"Bartok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jair","family":"Bar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Dushek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte M.","family":"Deane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yardena","family":"Samuels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2025.102506_bib1","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s43018-023-00588-x","article-title":"The landscape of T cell antigens for cancer immunotherapy","volume":"4","author":"Peri","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.xcrm.2025.102506_bib2","doi-asserted-by":"crossref","first-page":"E1555","DOI":"10.1073\/pnas.1521812113","article-title":"Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome","volume":"113","author":"Tripathi","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2025.102506_bib3","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102506_bib4","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature13988","article-title":"Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens","volume":"515","author":"Gubin","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102506_bib5","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2025.102506_bib6","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.coi.2016.07.005","article-title":"Neoantigens encoded in the cancer genome","volume":"41","author":"Schumacher","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.xcrm.2025.102506_bib7","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/ni.3682","article-title":"Final common pathway' of human cancer immunotherapy: targeting random somatic mutations","volume":"18","author":"Tran","year":"2017","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xcrm.2025.102506_bib8","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/s41573-023-00809-z","article-title":"T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome","volume":"22","author":"Klebanoff","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2025.102506_bib9","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1038\/s41467-021-24562-2","article-title":"Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting","volume":"12","author":"Bear","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102506_bib10","doi-asserted-by":"crossref","DOI":"10.1172\/JCI175790","article-title":"Natural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumors","volume":"134","author":"Bear","year":"2024","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2025.102506_bib11","article-title":"Systematic discovery and validation of T cell targets directed against oncogenic KRAS mutations","volume":"1","author":"Choi","year":"2021","journal-title":"Cell Rep. Methods"},{"key":"10.1016\/j.xcrm.2025.102506_bib12","doi-asserted-by":"crossref","first-page":"6389","DOI":"10.1038\/s41467-023-42010-1","article-title":"KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors","volume":"14","author":"Lu","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102506_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202451079","article-title":"Identification and structural characterization of a mutant KRAS-G12V specific TCR restricted by HLA-A3","volume":"54","author":"Sim","year":"2024","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.xcrm.2025.102506_bib14","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abd5515","article-title":"Bispecific antibodies targeting mutant RAS neoantigens","volume":"6","author":"Douglass","year":"2021","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.xcrm.2025.102506_bib15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40164-024-00504-8","article-title":"Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy","volume":"13","author":"Shao","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2025.102506_bib16","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2025.102506_bib17","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study","volume":"41","author":"Garassino","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102506_bib18","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102506_bib19","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41577-023-00973-8","article-title":"Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations","volume":"24","author":"Butterfield","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2025.102506_bib20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/sj.bjc.6605465","article-title":"Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses","volume":"102","author":"Liu","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.xcrm.2025.102506_bib21","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1182\/bloodadvances.2021006418","article-title":"Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy","volume":"6","author":"Fabrizio","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.xcrm.2025.102506_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001743","article-title":"Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy","volume":"9","author":"Nissani","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2025.102506_bib23","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/j.ymthe.2021.02.024","article-title":"Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity","volume":"29","author":"Murad","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2025.102506_bib24","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00262-022-03287-1","article-title":"Lymphodepleting chemotherapy practices and effect on safety and efficacy outcomes in patients with solid tumours undergoing T cell receptor-engineered T cell (TCR-T) Therapy: a systematic review and meta-analysis","volume":"72","author":"Owen","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.xcrm.2025.102506_bib25","article-title":"Combining chemotherapy with CAR-T cell therapy in treating solid tumors","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2025.102506_bib26","doi-asserted-by":"crossref","DOI":"10.1172\/JCI129466","article-title":"Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma","volume":"131","author":"Peri","year":"2021","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2025.102506_bib27","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1038\/s41596-019-0170-6","article-title":"Induction of neoantigen-reactive T cells from healthy donors","volume":"14","author":"Ali","year":"2019","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.xcrm.2025.102506_bib28","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1056\/NEJMoa2119662","article-title":"Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer","volume":"386","author":"Leidner","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102506_bib29","article-title":"Recurrent immunogenic neoantigens and their cognate T-cell receptors in treatment-resistant metastatic prostate cancer","author":"Gumpert","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2025.102506_bib30","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1016\/j.cell.2023.06.020","article-title":"Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy","volume":"186","author":"Dolton","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2025.102506_bib31","doi-asserted-by":"crossref","DOI":"10.1126\/science.abe9124","article-title":"Canonical T cell receptor docking on peptide-MHC is essential for T cell signaling","volume":"372","author":"Zareie","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2025.102506_bib32","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.immuni.2016.09.007","article-title":"Reversed T Cell Receptor Docking on a Major Histocompatibility Class I Complex Limits Involvement in the Immune Response","volume":"45","author":"Gras","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2025.102506_bib33","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1021\/acs.biochem.0c00689","article-title":"An Engineered T Cell Receptor Variant Realizes the Limits of Functional Binding Modes","volume":"59","author":"Singh","year":"2020","journal-title":"Biochemistry"},{"key":"10.1016\/j.xcrm.2025.102506_bib34","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jtho.2022.10.014","article-title":"First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations","volume":"18","author":"Paz-Ares","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.xcrm.2025.102506_bib35","article-title":"Efficacy of Immune Checkpoint Inhibition and Cytotoxic Chemotherapy in Mismatch Repair-Deficient and Microsatellite Instability-High Pancreatic Cancer: Mayo Clinic Experience","volume":"7","author":"Coston","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.xcrm.2025.102506_bib36","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1158\/1078-0432.CCR-06-1209","article-title":"Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration","volume":"13","author":"Bracci","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102506_bib37","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1158\/0008-5472.CAN-17-2153","article-title":"Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8(+) T Cells","volume":"78","author":"Johnson","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102506_bib38","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-14639-9","article-title":"Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma","volume":"11","author":"Kalaora","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102506_bib39","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1158\/2159-8290.CD-17-1418","article-title":"Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma","volume":"8","author":"Kalaora","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2025.102506_bib40","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/365264a0","article-title":"Gamma-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes","volume":"365","author":"Gaczynska","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102506_bib41","first-page":"354","article-title":"Role of proteasomes in antigen presentation","volume":"47","author":"Gaczynska","year":"1993","journal-title":"Enzyme Protein"},{"key":"10.1016\/j.xcrm.2025.102506_bib42","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.coi.2012.11.004","article-title":"The immunoproteasome in antigen processing and other immunological functions","volume":"25","author":"Basler","year":"2013","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.xcrm.2025.102506_bib43","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/B978-0-12-397863-9.00003-1","article-title":"Immunoproteasomes: structure, function, and antigen presentation","volume":"109","author":"Ferrington","year":"2012","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.xcrm.2025.102506_bib44","doi-asserted-by":"crossref","first-page":"L328","DOI":"10.1152\/ajplung.00156.2016","article-title":"Proteasome function shapes innate and adaptive immune responses","volume":"311","author":"Kammerl","year":"2016","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.xcrm.2025.102506_bib45","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1158\/1535-7163.MCT-23-0931","article-title":"Immunoproteasome Activation Expands the MHC Class I Immunopeptidome, Unmasks Neoantigens, and Enhances T-cell Anti-Myeloma Activity","volume":"23","author":"Rana","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.xcrm.2025.102506_bib46","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1158\/2326-6066.CIR-15-0188","article-title":"Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors","volume":"4","author":"Wang","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.xcrm.2025.102506_bib47","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1438107","article-title":"Gemcitabine alters the proteasome composition and immunopeptidome of tumour cells","volume":"7","author":"Gravett","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.xcrm.2025.102506_bib48","article-title":"Chemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cells","volume":"7","author":"Wan","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2025.102506_bib49","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s00432-003-0492-0","article-title":"Increased expression of CEA and MHC class I in colorectal cancer cell lines exposed to chemotherapy drugs","volume":"129","author":"Ohtsukasa","year":"2003","journal-title":"J Cancer Res Clin"},{"key":"10.1016\/j.xcrm.2025.102506_bib50","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1074\/mcp.TIR117.000383","article-title":"High-throughput and Sensitive Immunopeptidomics Platform Reveals Profound Interferongamma-Mediated Remodeling of the Human Leukocyte Antigen (HLA) Ligandome","volume":"17","author":"Chong","year":"2018","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.xcrm.2025.102506_bib51","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s43018-023-00557-4","article-title":"The proteasome regulator PSME4 modulates proteasome activity and antigen diversity to abrogate antitumor immunity in NSCLC","volume":"4","author":"Javitt","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.xcrm.2025.102506_bib52","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3389\/fonc.2020.00070","article-title":"Immunotherapy Potentiates the Effect of Chemotherapy in Metastatic Melanoma-A Retrospective Study","volume":"10","author":"Hadash-Bengad","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xcrm.2025.102506_bib53","doi-asserted-by":"crossref","DOI":"10.4161\/onci.23714","article-title":"Dacarbazine mediate antimelanoma effects via NK cells","volume":"2","author":"Hervieu","year":"2013","journal-title":"OncoImmunology"},{"key":"10.1016\/j.xcrm.2025.102506_bib54","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/jid.2012.273","article-title":"Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth","volume":"133","author":"Hervieu","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.xcrm.2025.102506_bib55","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jmb.2015.09.014","article-title":"The HADDOCK2.2 Web Server: User-Friendly Integrative Modeling of Biomolecular Complexes","volume":"428","author":"van Zundert","year":"2016","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.xcrm.2025.102506_bib56","doi-asserted-by":"crossref","first-page":"D406","DOI":"10.1093\/nar\/gkx971","article-title":"STCRDab: the structural T-cell receptor database","volume":"46","author":"Leem","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2025.102506_bib57","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1038\/s41418-024-01370-x","article-title":"Inhibition of nucleo-cytoplasmic proteasome translocation by the aromatic amino acids or silencing Sestrin3-their sensing mediator-is tumor suppressive","volume":"31","author":"Livneh","year":"2024","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.xcrm.2025.102506_bib58","doi-asserted-by":"crossref","first-page":"W739","DOI":"10.1093\/nar\/gkac382","article-title":"SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2025.102506_bib59","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.ccell.2025.03.003","article-title":"Translation dysregulation in cancer as a source for targetable antigens","volume":"43","author":"Weller","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2025.102506_bib60","doi-asserted-by":"crossref","first-page":"W90","DOI":"10.1093\/nar\/gkw377","article-title":"Enrichr: a comprehensive gene set enrichment analysis web server 2016 update","volume":"44","author":"Kuleshov","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2025.102506_bib61","article-title":"Protein complex prediction with AlphaFold-Multimer","author":"Evans","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.xcrm.2025.102506_bib62","author":"Teixeira"},{"key":"10.1016\/j.xcrm.2025.102506_bib63","doi-asserted-by":"crossref","first-page":"W530","DOI":"10.1093\/nar\/gkab294","article-title":"PLIP 2021: expanding the scope of the protein-ligand interaction profiler to DNA and RNA","volume":"49","author":"Adasme","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2025.102506_bib64","doi-asserted-by":"crossref","DOI":"10.1093\/bioinformatics\/btaf566","article-title":"STCRpy: a software suite for T cell receptor structure parsing, interaction profiling and machine learning dataset preparation","volume":"41","author":"Quast","year":"2025","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2025.102506_bib65","doi-asserted-by":"crossref","first-page":"6034","DOI":"10.4049\/jimmunol.1202830","article-title":"Mutated PPP1R3B Is Recognized by T Cells Used To Treat a Melanoma Patient Who Experienced a Durable Complete Tumor Regression","volume":"190","author":"Lu","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.xcrm.2025.102506_bib66","doi-asserted-by":"crossref","first-page":"40778","DOI":"10.18632\/oncotarget.17253","article-title":"Pancreatic cancer ascites xenograft-an expeditious model mirroring advanced therapeutic resistant disease","volume":"8","author":"Golan","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.xcrm.2025.102506_bib67","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.cell.2017.09.050","article-title":"MHC-I Genotype Restricts the Oncogenic Mutational Landscape","volume":"171","author":"Marty","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2025.102506_bib68","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.4049\/jimmunol.1700893","article-title":"NetMHCpan-4.0: Improved Peptide-MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data","volume":"199","author":"Jurtz","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.xcrm.2025.102506_bib69","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.xcrm.2025.102506_bib70","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/MOU.0000000000001000","article-title":"Papillary renal cell carcinoma: current and controversial issues","volume":"32","author":"Angori","year":"2022","journal-title":"Curr. Opin. Urol."},{"key":"10.1016\/j.xcrm.2025.102506_bib71","first-page":"203","article-title":"NCCN Practice Guidelines for Colorectal Cancer","volume":"14","author":"Benson","year":"2000","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.xcrm.2025.102506_bib72","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.3748\/wjg.v28.i12.1187","article-title":"Epidemiology of stomach cancer","volume":"28","author":"Ilic","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.xcrm.2025.102506_bib73","series-title":"StatPearls","article-title":"Endometrial Cancer","author":"Mahdy","year":"2024"},{"key":"10.1016\/j.xcrm.2025.102506_bib74","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1158\/1078-0432.CCR-11-2370","article-title":"Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities","volume":"18","author":"Perez-Moreno","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102506_bib75","first-page":"159","article-title":"Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer","volume":"31","author":"Pishvaian","year":"2017","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.xcrm.2025.102506_bib76","doi-asserted-by":"crossref","DOI":"10.3390\/medsci8010015","article-title":"Epidemiology of Bladder Cancer","volume":"8","author":"Saginala","year":"2020","journal-title":"Med. Sci."},{"key":"10.1016\/j.xcrm.2025.102506_bib77","article-title":"TRPs in Ovarian Serous Cystadenocarcinoma: The Expression Patterns, Prognostic Roles, and Potential Therapeutic Targets","volume":"9","author":"Zhang","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.xcrm.2025.102506_bib78","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.immuni.2017.02.007","article-title":"Mass Spectrometry Profiling of HLA-Associated Peptidomes in Mono-allelic Cells Enables More Accurate Epitope Prediction","volume":"46","author":"Abelin","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2025.102506_bib79","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/nbt.1511","article-title":"MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification","volume":"26","author":"Cox","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2025.102506_bib80","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab","volume":"171","author":"Riaz","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2025.102506_bib81","doi-asserted-by":"crossref","first-page":"D948","DOI":"10.1093\/nar\/gkae1071","article-title":"Ensembl 2025","volume":"53","author":"Dyer","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2025.102506_bib82","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/nprot.2017.147","article-title":"Proteome-wide identification of ubiquitin interactions using UbIA-MS","volume":"13","author":"Zhang","year":"2018","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.xcrm.2025.102506_bib83","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2025.102506_bib84","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1093\/bioinformatics\/btv105","article-title":"specL--an R\/Bioconductor package to prepare peptide spectrum matches for use in targeted proteomics","volume":"31","author":"Panse","year":"2015","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2025.102506_bib85","doi-asserted-by":"crossref","first-page":"5063","DOI":"10.1038\/s41467-023-40821-w","article-title":"Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigen","volume":"14","author":"Wright","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102506_bib86","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The Protein Data Bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2025.102506_bib87","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/prot.22488","article-title":"Improved prediction of protein side-chain conformations with SCWRL4","volume":"77","author":"Krivov","year":"2009","journal-title":"Proteins"},{"key":"10.1016\/j.xcrm.2025.102506_bib88","article-title":"T-cell receptor structures and predictive models reveal comparable alpha and beta chain structural diversity despite differing genetic complexity","author":"Quast","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.xcrm.2025.102506_bib89","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1038\/s41467-022-31492-0","article-title":"dia-PASEF data analysis using FragPipe and DIA-NN for deep proteomics of low sample amounts","volume":"13","author":"Demichev","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102506_bib90","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99488","article-title":"Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model","volume":"3","author":"Jin","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.xcrm.2025.102506_bib91","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1016\/j.molcel.2023.08.016","article-title":"Regulation of nucleo-cytosolic 26S proteasome translocation by aromatic amino acids via mTOR is essential for cell survival under stress","volume":"83","author":"Livneh","year":"2023","journal-title":"Mol. Cell"}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125005798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125005798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:55:07Z","timestamp":1790265307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379125005798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":91,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2666379125005798"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102506","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lymphodepleting chemotherapy potentiates neoantigen-directed T cell therapy by enhancing antigen presentation","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102506","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102506"}}